title: What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?
authors.affiliation: Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. sgiralt@mdanderson.org
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Edward
authors.initials: E
authors.lastname: Stadtmauer
authors.forename: Phillip
authors.initials: P
authors.lastname: McCarthy
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000592:standards; D018450:Disease Progression; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents